Reading CCCC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CCCC free→Reading CCCC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CCCC free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral, and earnings quality cannot be assessed as the company was unprofitable over the past year. Management's recent track record has been fairly steady, but risk is elevated, and the sector backdrop is a headwind. Peer multiples imply a price about 44% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples, but recent financials are weak. Key factors to watch include guidance changes and sector trends, as these could significantly impact performance. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $3.82. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $3.82 CCCC trades at 7× p/s, below its 9× p/s peer median. Our $6.67 fair value sits above the price; medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price sits about 43% below a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.92x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates.
5 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.29 → $-0.23 (+22.0% / 30d). 1 raised, 0 cut, 4 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 100% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$323.
How much price usually moves either way.
On a bad day, this stock has moved -$829.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $5,210.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Valuation label changed from 'inexpensive' to 'full'.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for CCCC yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Principal Accounting Officer On May 12, 2026, C4 Therapeutics, Inc. (the “Company”) determined that Mark Mossler will no longer serve as the Company’s Chief Accounting Officer, effective May 15, 2026. Mr. Mossler’s departure from the Company is not due to any disagreement with the Company or the Company’s Board of Directors on any matt…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
CCCC C4 Therapeutics Inc | Typical Show detailsSector percentile: 61 of 100 | full | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 78 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Ensure current cash, cash equivalents, and marketable securities fund operations to the end of 2028.
Stated in 3 of last 3 quarters. Management has consistently stated that current cash resources will fund operations through 2028. However, operating cash flow remains negative, with a cash outflow of $29.94M in 2026-Q1, indicating limited progress in improving cash flow sustainability.
“The company expects that its current cash, cash equivalents and marketable securities will fund its operations to the end of 2028.”
“The company expects that its current cash, cash equivalents and marketable securities will enable it to fund its operating plan to the end of 2028.”
“The company expects that its current cash, cash equivalents and marketable securities will enable the company to fund its operating plan to the end of 2028.”
Collaborate with Roche on the discovery, development, and commercialization of degrader-antibody conjugates.
Newly stated in 2026-Q1. The strategic partnership with Roche aims to advance the development of degrader-antibody conjugates. This collaboration is a positive step towards growth, but financial impact is yet to be seen as revenue decreased from $11.02M in 2025-Q4 to $6.15M in 2026-Q1, indicating limited immediate financial benefit.
“C4 Therapeutics entered into a Research Collaboration and License Agreement with Roche to collaborate on DACs.”
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “ Exchange Act ”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Entry into a Material Definitive Agreement. On April 8, 2026 , C4 Therapeutics, Inc. (“ C4T ”) entered into a Research Collaboration and License Agreement ( the “ License Agreement ”) with F. Hoffmann-La Roche Ltd. (“ Roche Basel ”) and Hoffmann-La Roche Inc. (“ Roche US ”, and together with Roche Basel, “ Roche ”) to collaborate on the discovery, development and commercialization of degrader-antibody conjugates (“ DACs ”), an emerging modality designed to selectively target and neutralize di…
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “ Exchange Act ”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 , as amended (the “ Securities Act ”), or the Exchange Act, except as expressly set forth by specific reference in…